Education
About Us
Working with TipRanks
Follow Us
Vertex Pharmaceuticals (VRTX)
NASDAQ:VRTX
VRTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$377.85 - $519.88
Previous CloseN/A
Volume295.43K
Average Volume (3M)1.60M
Market Cap
$115.69B
Enterprise Value$121.26B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Jul 31, 2025EPS Estimate
4.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.06
Shares Outstanding257,080,840
10 Day Avg. Volume1,428,933
30 Day Avg. Volume1,602,149
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda249.35
Forecast
1Y Price Target
$513.90Price Target Upside20.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering27
---
Bulls Say, Bears Say
Bulls Say
Pipeline ProgressVertex has secured material coverage access for Journavx, with sales expected to start materializing in the third quarter.
Product LaunchVertex launched Alyftrek, its next-generation triple therapy for cystic fibrosis, which is expected to be accretive to Vertex over time due to a lower royalty burden.
Strategic GrowthVertex came out as a winner by negotiating a single study rather than two different studies for nephrotic and subnephrotic patients, thereby increasing the patient base.
Bears Say
Financial PerformanceVRTX delivered a rare miss across the board on both revenue and EPS.
Market ValuationThe premium valuation of Vertex shares is currently at a P/E multiple of 31.6x compared to the mega-cap BioPharma peer average of 15.7x.
Product DistributionThe logistics of the Casgevy therapy are extensive, making it unclear how quickly sales may accelerate or contribute meaningfully to revenue or margins.
---
Ownership Overview
0.21% Insiders
36.69% Mutual Funds
0.50% Other Institutional Investors
37.61% Public Companies and
Individual Investors
VRTX FAQ
What was Vertex Pharmaceuticals’s price range in the past 12 months?
Vertex Pharmaceuticals lowest stock price was $377.85 and its highest was $519.88 in the past 12 months.
What is Vertex Pharmaceuticals’s market cap?
Vertex Pharmaceuticals’s market cap is $115.69B.
When is Vertex Pharmaceuticals’s upcoming earnings report date?
Vertex Pharmaceuticals’s upcoming earnings report date is Jul 31, 2025 which is in 82 days.
How were Vertex Pharmaceuticals’s earnings last quarter?
Vertex Pharmaceuticals released its earnings results on May 05, 2025. The company reported $4.06 earnings per share for the quarter, missing the consensus estimate of $4.245 by -$0.185.
Is Vertex Pharmaceuticals overvalued?
According to Wall Street analysts Vertex Pharmaceuticals’s price is currently Undervalued.
Does Vertex Pharmaceuticals pay dividends?
Vertex Pharmaceuticals does not currently pay dividends.
What is Vertex Pharmaceuticals’s EPS estimate?
Vertex Pharmaceuticals’s EPS estimate is 4.3.
How many shares outstanding does Vertex Pharmaceuticals have?
Vertex Pharmaceuticals has 257,080,840 shares outstanding.
What happened to Vertex Pharmaceuticals’s price movement after its last earnings report?
Vertex Pharmaceuticals reported an EPS of $4.06 in its last earnings report, missing expectations of $4.245. Following the earnings report the stock price went down -10.028%.
Which hedge fund is a major shareholder of Vertex Pharmaceuticals?
Currently, no hedge funds are holding shares in VRTX
---
Vertex Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$513.90 (20.92% Upside)
$513.90 (20.92% Upside)
Blogger Sentiment
Bullish
VRTX Sentiment 96%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 230.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.80%
12-Months-Change
Fundamentals
Return on Equity
-5.64%
Trailing 12-Months
Asset Growth
-4.34%
Trailing 12-Months
Company Description
Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
---
VRTX Company Deck
---
VRTX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Vertex Pharmaceuticals demonstrated strong revenue growth and successful product launches in the U.S., but faced challenges with ex-U.S. revenue decline and increased operating expenses. The pipeline is advancing well with multiple programs in pivotal development, although the temporary pause in the VX-522 study represents a setback. Financial guidance for the year was raised, reflecting confidence in continued growth.Read More>---
VRTX Revenue Breakdown
60.66% U.S.
39.34% Europe
---
VRTX Stock 12 Month Forecast
Average Price Target
$513.90
▲(20.92% Upside)
Technical Analysis
---